210 related articles for article (PubMed ID: 33642251)
1. ["Alternative study designs" for the evaluation of digital health applications - a real alternative?].
Gensorowsky D; Lampe D; Hasemann L; Düvel J; Greiner W
Z Evid Fortbild Qual Gesundhwes; 2021 Apr; 161():33-41. PubMed ID: 33642251
[TBL] [Abstract][Full Text] [Related]
2. Dynamic HTA for digital health solutions: opportunities and challenges for patient-centered evaluation.
Brönneke JB; Herr A; Reif S; Stern AD
Int J Technol Assess Health Care; 2023 Nov; 39(1):e72. PubMed ID: 37973549
[TBL] [Abstract][Full Text] [Related]
3. [How robust are studies of currently permanently included digital health applications (DiGA)? Methodological quality of studies demonstrating positive health care effects of DiGA].
Kolominsky-Rabas PL; Tauscher M; Gerlach R; Perleth M; Dietzel N
Z Evid Fortbild Qual Gesundhwes; 2022 Dec; 175():1-16. PubMed ID: 36437182
[TBL] [Abstract][Full Text] [Related]
4. [Digital Health Applications: A Qualitative Study of Approaches to Improve Access to Statutory Health Insurance].
Düvel JA; Gensorowsky D; Hasemann L; Greiner W
Gesundheitswesen; 2022 Jan; 84(1):64-74. PubMed ID: 33636736
[TBL] [Abstract][Full Text] [Related]
5. Market access and value-based pricing of digital health applications in Germany.
Gensorowsky D; Witte J; Batram M; Greiner W
Cost Eff Resour Alloc; 2022 Jun; 20(1):25. PubMed ID: 35698135
[TBL] [Abstract][Full Text] [Related]
6. [The new approval process for the reimbursement of digital health applications (DiGA) from the perspective of the German statutory health insurance].
Gregor-Haack J; Busse T; Hagenmeyer EG
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2021 Oct; 64(10):1220-1227. PubMed ID: 34459939
[TBL] [Abstract][Full Text] [Related]
7. [Relevance of different study types in benefit assessment: Results from expert interviews].
Toews I; Bode S; Metzner G; Farin-Glattacker E; Meerpohl JJ
Z Evid Fortbild Qual Gesundhwes; 2021 Dec; 167():25-32. PubMed ID: 34556460
[TBL] [Abstract][Full Text] [Related]
8. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
9. Evidence requirements of permanently listed digital health applications (DiGA) and their implementation in the German DiGA directory: an analysis.
Mäder M; Timpel P; Schönfelder T; Militzer-Horstmann C; Scheibe S; Heinrich R; Häckl D
BMC Health Serv Res; 2023 Apr; 23(1):369. PubMed ID: 37069592
[TBL] [Abstract][Full Text] [Related]
10. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
11. [Evidence of positive care effects by digital health apps-methodological challenges and approaches].
König IR; Mittermaier M; Sina C; Raspe M; Stais P; Gamstätter T; Stachwitz P; Wolfrum S; Richter JG; Möckel M;
Inn Med (Heidelb); 2022 Dec; 63(12):1298-1306. PubMed ID: 36279007
[TBL] [Abstract][Full Text] [Related]
12. [Benefit assessment of digital health applications-challenges and opportunities].
Hemkens LG
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2021 Oct; 64(10):1269-1277. PubMed ID: 34524477
[TBL] [Abstract][Full Text] [Related]
13. Integration of digital health applications into the German healthcare system: development of "The DiGA-Care Path".
Giebel GD; Abels C; Börchers K; Kampka B; Neusser S; Cissarek HR; Plescher F; Wasem J; Blase N
Front Health Serv; 2024; 4():1372522. PubMed ID: 38545382
[TBL] [Abstract][Full Text] [Related]
14. Evaluation Methods Applied to Digital Health Interventions: What Is Being Used beyond Randomised Controlled Trials?-A Scoping Review.
Hrynyschyn R; Prediger C; Stock C; Helmer SM
Int J Environ Res Public Health; 2022 Apr; 19(9):. PubMed ID: 35564616
[TBL] [Abstract][Full Text] [Related]
15. [Digital health applications: statutory introduction of patient-centred digital innovations into healthcare].
Ludewig G; Klose C; Hunze L; Matenaar S
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2021 Oct; 64(10):1198-1206. PubMed ID: 34529096
[TBL] [Abstract][Full Text] [Related]
16. Individual health services.
Schnell-Inderst P; Hunger T; Hintringer K; Schwarzer R; Seifert-Klauss VR; Gothe H; Wasem J; Siebert U
GMS Health Technol Assess; 2011; 7():Doc05. PubMed ID: 21966301
[TBL] [Abstract][Full Text] [Related]
17. [Procedures and methods of benefit assessments for medicines in Germany].
Bekkering GE; Kleijnen J
Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
[TBL] [Abstract][Full Text] [Related]
18. Overview of the epidemiology methods and applications: strengths and limitations of observational study designs.
Colditz GA
Crit Rev Food Sci Nutr; 2010; 50 Suppl 1(s1):10-2. PubMed ID: 21132580
[TBL] [Abstract][Full Text] [Related]
19. [Technology assessment of digital health applications for reimbursement decisions].
Jeindl R; Wild C
Wien Med Wochenschr; 2024 Mar; 174(3-4):44-52. PubMed ID: 34529150
[TBL] [Abstract][Full Text] [Related]
20. The German Fast Track Toward Reimbursement of Digital Health Applications: Opportunities and Challenges for Manufacturers, Healthcare Providers, and People With Diabetes.
Schliess F; Affini Dicenzo T; Gaus N; Bourez JM; Stegbauer C; Szecsenyi J; Jacobsen M; Müller-Wieland D; Kulzer B; Heinemann L
J Diabetes Sci Technol; 2024 Mar; 18(2):470-476. PubMed ID: 36059268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
